TUSTIN, Calif., March 6, 2023 (GLOBE NEWSWIRE) — Avid Bioservices, Inc. CDMO, a specialty biologics contract development and manufacturing company (CDMO) working to improve patients’ lives by providing quality services to biotechnology and pharmaceutical companies, today announced that it has reported financial results for the third quarter of fiscal 2023 will be announced on March 13, 2023. after market close and will host a webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Members of Avid’s management team will discuss the third quarter financial results and review recent company developments.

To listen to the live webcast or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.

Around Avid Bioservices, Inc.

Avid Bioservices CDMO, an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on the development and CGMP manufacture of biologics. The company offers a full range of process development, CGMP services for clinical and commercial manufacturing to the biotechnology and biopharmaceutical industries. With 30 years of experience manufacturing monoclonal antibodies and recombinant proteins, Avid’s services include clinical and commercial CGMP drug manufacturing, bulk packaging, clearance and stability testing, and regulatory submission support. For early stage programs, the Company offers a variety of process development activities including upstream and downstream development and optimization, analytical method development, testing and characterization. The scope of our services ranges from stand-alone process development projects to complete development and manufacturing programs to commercialization. www.avidbio.com

Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com